NT-077 is under clinical development by Xero Pharmaceuticals and currently in Phase I for Axillary Hyperhidrosis. According to GlobalData, Phase I drugs for Axillary Hyperhidrosis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NT-077’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NT-077 is under development for the treatment of axillary hyperhidrosis. The drug candidate is a repurposed anticholinergic medicine and is administered through topical route in the form of spray.
Xero Pharmaceuticals overview
Xero Pharmaceuticals is a specialty pharmaceutical company developing medicines for primary axillary hyperhidrosis and excessive underarms sweating.
For a complete picture of NT-077’s drug-specific PTSR and LoA scores, buy the report here.